Anti-Mouse CD29 (Clone KMI6) – Purified in vivo PLATINUM™ Functional Grade

The most common in vivo applications of clone KMI6 (anti-mouse CD29/Integrin β1) in mice are for CD29 (Integrin β1) neutralization to study roles in cell adhesion, immune cell trafficking, and inflammation, as well as for investigating disease models characterized by integrin β1 involvement.

Key in vivo uses include:

• Blocking or neutralizing CD29 (Integrin β1) function to probe its biological role in mouse models, especially where cell adhesion or integrin-mediated signaling is critical.
• Therapeutic intervention studies, such as experiments in collagen-induced arthritis, where KMI6 injection suppressed inflammatory processes like joint swelling and cartilage erosion by inhibiting pathways downstream of CD29 (including MMP-9 activity).
• Functional studies in immunology, to dissect CD29's role in lymphohemopoietic tissues, leukocyte migration, and immune cell interactions.

Reported applications from manufacturers and research reports include:

• In vivo CD29 neutralization (the primary in vivo use for function blocking studies).
• In vitro applications relevant to in vivo contexts (sometimes studies begin in vitro before animal work), such as flow cytometry, immunofluorescence, and immunoprecipitation.

The KMI6 antibody's binding epitope is widely distributed, but in vivo expression can be most prominent within lymphohemopoietic tissues, making these areas common targets of in vivo research.

Less commonly, KMI6 is used in:

• Cancer and inflammatory disease models to correlate CD29’s role with disease progression and therapy response, as integrins are significant in both tumor biology and tissue inflammation.

Clone KMI6 is not typically used for depletion (i.e., cell ablation) but rather for functional blockade (neutralization) of CD29 activity in vivo.

Summary Table of Main In Vivo Applications

These applications are foundational in studying integrin β1/CD29-mediated biology in vivo, especially when genetic knockout is not feasible or rapid pharmacologic intervention is needed.

Commonly, antibodies or proteins used with KMI6—which targets mouse integrin β1 (CD29)—in scientific literature and applications are:

• Other integrin subunits/partners: KMI6 (anti-CD29) is frequently used alongside antibodies targeting integrin α-chains (such as CD49a-f) to study specific VLA (very late antigen) integrin complexes:

  • CD49a (VLA-1, α1)
  • CD49b (VLA-2, α2)
  • CD49c (VLA-3, α3)
  • CD49d (VLA-4, α4)
  • CD49e (VLA-5, α5)
  • CD49f (VLA-6, α6)
  • Sometimes CD51 (αV), for αVβ1 complexes.

• Extracellular matrix (ECM) ligands: Since CD29/integrin β1 recognizes and binds ECM proteins, experiments with KMI6 often also reference or use:

  • Fibronectin
  • Collagen
  • Laminin
  • Vitronectin.

• Cell surface markers and flow cytometry panels: KMI6 is included in multicolor flow cytometry panels and may be used with:

  • CD44
  • CD45
  • CD31
  • Other lineage or stem cell markers, especially in stromal or hematopoietic cell studies.

• Isotype controls: For proper validation, a rat IgG2a isotype control antibody is frequently paired with KMI6 if it is a rat IgG2a clone, to control for background staining.

• Functional and activation studies: KMI6 (as an activating antibody) is sometimes used with:

  • Other integrin-blocking or activating antibodies (e.g., anti-CD49d to block VLA-4 function)
  • Functional ligands such as VCAM-1 and MadCAM-1 for binding and migration assays.

• Detection of integrin complexes: KMI6 may be used in immunoprecipitation, immunoblotting/Western blot, and immunohistochemistry and often is co-applied with antibodies against related β or α subunits to confirm heterodimer formation or cellular localization.

Summary Table: Common Antibodies/Proteins Used with KMI6

In sum, KMI6 is typically paired with antibodies identifying its heterodimer partners (integrin α subunits), cell surface markers for subset analysis, relevant ECM proteins/ligands, and appropriate controls depending on experimental design.

Key findings from scientific literature citing clone KMI6 focus on its use as an antibody specific for mouse CD29 (integrin β1), which is pivotal in studies of cell adhesion, migration, and signaling across multiple cell types. Research employing KMI6 has revealed several important insights:

• Beta 1 integrin (CD29) detection: KMI6 is used extensively to detect β1 integrin on mouse cells, including leukocytes, endothelial, smooth muscle, and epithelial cells. This has supported studies on integrin-mediated cell adhesion, migration, trafficking, and differentiation, both in physiological and pathological contexts.

• Functional assays and applications: The KMI6 antibody has been validated for use in flow cytometry, immunoprecipitation, immunoblotting, and immunohistology, especially for the identification and localization of integrin β1 in tissues and cell populations.

• Cell–matrix interactions: KMI6 has been key in experiments demonstrating that β1 integrin mediates cell–matrix adhesions. For instance, it was used to show that knockout or reconstitution of TRPV4 impacts β1 integrin-mediated cell adhesion on collagen matrices, highlighting integrin’s regulatory role in mechanobiology and extracellular matrix engagement.

• Integrin signaling and immune function: Studies have used immobilized KMI6 antibodies to activate β1 integrin in vitro, which can enhance signals like GM-CSF–driven differentiation of hematopoietic cells, indicating a role for integrin engagement in modulating cytokine responses and immune cell function.

• Focal adhesion-independent migration: KMI6 was used to investigate integrin α4β1's role in cell migration and spreading independent of focal adhesion kinase (FAK), supporting that integrin signaling can drive unique migratory behavior in the absence of canonical adhesion signaling.

• Quality and specificity: KMI6 detects a ~120 kDa β1 integrin band by immunoblotting under non-reducing conditions and has high specificity and purity, minimizing cross-reactivity and aggregation concerns.

In summary, clone KMI6 is a validated tool for detecting, quantifying, and functionally activating mouse β1 integrin. Its use has furthered understanding of cell adhesion, migration, immune function, and mechanotransduction in murine models, particularly in contexts demanding precise localization and functional studies of integrin β1.

Dosing regimens for clone KMI6 (anti-mouse CD29/integrin β1) in mouse models are not standardized across all studies, but available reports indicate a typical dose of 10 mg/kg administered intraperitoneally (i.p.) has been used effectively in in vivo settings.

No comprehensive dataset summarizes variation across all mouse models, but context-specific factors may influence dosing:

• Mouse strain and disease model: The KMI6 antibody was raised against bone marrow stromal cells from a C57BL/6 x DBA/2 mouse, and it has been used in models such as myocardial infarction (MI) where 10 mg/kg i.p. was administered.
• Route of administration: Intraperitoneal injection is a standard method for KMI6 delivery in vivo studies.
• Dosing frequency: Specific interval and repetition details are seldom uniformly reported for KMI6, though similar antibodies targeting cell-surface molecules in mouse models are often given once or on a repeated schedule depending on the experimental goal.

Other essential details:

• The KMI6 antibody is commonly used for both in vivo neutralization and in vitro studies, but higher concentrations/doses may be required for in vivo efficacy compared to in vitro settings.
• Product supplier datasheets and published studies frequently recommend starting at 10 mg/kg for in vivo experiments, with deviations based on experimental requirements and pilot titrations.

In summary:

• The most documented dosing regimen for KMI6 is 10 mg/kg i.p. per administration in mouse models of disease such as myocardial infarction.
• Specific regimens (frequency or adaptation to specific strains/disease contexts) are not widely published, so consulting primary literature or conducting dose-ranging pilots may be necessary for novel applications.

If you have a particular disease model or application in mind, more tailored dosing information may be available in context-specific primary studies.